Loading...

We've got a brand new version of Simply Wall St! Try it out

Australis Capital

CNSX:AUSA
Snowflake Description

Excellent balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
AUSA
CNSX
CA$118M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Australis Capital Inc. is a venture capital specializing in early-stage but not limited to equity positions and/or debt in both public and private companies, financings in exchange for royalties or other distribution streams, and control share acquisitions and buyouts. The last earnings update was 25 days ago. More info.


Add to Portfolio Compare Print
  • Australis Capital is a fund or ETF! Currently our data availability for these is poor, we only recommend using them as part of a portfolio.
  • Australis Capital has significant price volatility in the past 3 months.
AUSA Share Price and Events
7 Day Returns
-22.1%
CNSX:AUSA
-5.9%
CA Pharmaceuticals
1.3%
CA Market
1 Year Returns
-76.6%
CNSX:AUSA
-46.7%
CA Pharmaceuticals
-0.1%
CA Market
AUSA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Australis Capital (AUSA) -22.1% -16.9% -21.3% -76.6% - -
CA Pharmaceuticals -5.9% -3.4% -24.8% -46.7% 217.3% 286.4%
CA Market 1.3% 4.2% 1.6% -0.1% 8.4% 5.7%
1 Year Return vs Industry and Market
  • AUSA underperformed the Pharmaceuticals industry which returned -46.7% over the past year.
  • AUSA underperformed the Market in Canada which returned -0.1% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

AUSA Value

 Is Australis Capital undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Australis Capital. This is due to cash flow or dividend data being unavailable. The share price is CA$0.74.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Australis Capital's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Australis Capital's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:AUSA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in CAD CA$-0.02
CNSX:AUSA Share Price ** CNSX (2019-09-20) in CAD CA$0.74
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 15.3x
Canada Market PE Ratio Median Figure of 539 Publicly-Listed Companies 14.14x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Australis Capital.

CNSX:AUSA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:AUSA Share Price ÷ EPS (both in CAD)

= 0.74 ÷ -0.02

-34.51x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Australis Capital is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • Australis Capital is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Australis Capital's expected growth come at a high price?
Raw Data
CNSX:AUSA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -34.51x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
-38.5%per year
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.56x
Canada Market PEG Ratio Median Figure of 245 Publicly-Listed Companies 1.02x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Australis Capital, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Australis Capital's assets?
Raw Data
CNSX:AUSA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in CAD CA$0.47
CNSX:AUSA Share Price * CNSX (2019-09-20) in CAD CA$0.74
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.36x
Canada Market PB Ratio Median Figure of 2,457 Publicly-Listed Companies 1.43x
CNSX:AUSA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:AUSA Share Price ÷ Book Value per Share (both in CAD)

= 0.74 ÷ 0.47

1.58x

* Primary Listing of Australis Capital.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Australis Capital is good value based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess Australis Capital's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Australis Capital has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

AUSA Future Performance

 How is Australis Capital expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-38.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Australis Capital expected to grow at an attractive rate?
  • Unable to compare Australis Capital's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Australis Capital's earnings growth to the Canada market average as it is expected to be loss making during the next 1-3 years.
  • Australis Capital's revenues are expected to decrease over the next 1-3 years, this is below the Canada market average.
Annual Growth Rates Comparison
Raw Data
CNSX:AUSA Future Growth Rates Data Sources
Data Point Source Value (per year)
CNSX:AUSA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts -38.5%
CNSX:AUSA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts -24%
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 97.7%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 56.5%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.6%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:AUSA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:AUSA Future Estimates Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-03-31 0 -6 1
2020-03-31 0 -6 1
CNSX:AUSA Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-06-30 0 -3 -3
2019-03-31 0 -3 -4
2018-12-31 0 -2 -5
2018-09-30 -1 -4
2018-06-30 0 -2
2018-03-31 0 0
2017-03-31 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Australis Capital is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Australis Capital's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:AUSA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Australis Capital Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:AUSA Future Estimates Data
Date (Data in CAD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-03-31 -0.04 -0.04 -0.04 1.00
2020-03-31 -0.04 -0.04 -0.04 1.00
CNSX:AUSA Past Financials Data
Date (Data in CAD Millions) EPS *
2019-06-30 -0.02
2019-03-31 -0.04
2018-12-31 -0.03
2018-09-30 -0.03
2018-06-30 -0.06
2018-03-31
2017-03-31

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Australis Capital will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Australis Capital's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Australis Capital has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

AUSA Past Performance

  How has Australis Capital performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Australis Capital's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Australis Capital does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Australis Capital's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Australis Capital's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Australis Capital's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Australis Capital Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:AUSA Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 0.20 -2.73 6.46
2019-03-31 0.13 -4.17 3.88
2018-12-31 0.13 -4.92 2.37
2018-09-30 -3.86 0.38
2018-06-30 -1.73 0.00
2018-03-31 -0.04 0.00
2017-03-31 -0.05 0.01

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Australis Capital has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Australis Capital has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Australis Capital improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Australis Capital's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Australis Capital has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

AUSA Health

 How is Australis Capital's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Australis Capital's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Australis Capital is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Australis Capital's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Australis Capital's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 202.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Australis Capital Company Filings, last reported 2 months ago.

CNSX:AUSA Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 74.20 0.13 13.60
2019-03-31 60.67 0.00 8.56
2018-12-31 58.66 0.20 6.05
2018-09-30 21.72 0.00 4.75
2018-06-30 4.16 0.00 0.00
2018-03-31 -0.16 3.14
2017-03-31 -0.12 1.81 0.00
  • Australis Capital's level of debt (0.2%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Australis Capital's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Australis Capital has sufficient cash runway for more than 3 years based on current free cash flow.
  • Australis Capital has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 119.7% each year.
X
Financial health checks
We assess Australis Capital's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Australis Capital has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

AUSA Dividends

 What is Australis Capital's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Australis Capital dividends.
If you bought CA$2,000 of Australis Capital shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Australis Capital's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Australis Capital's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:AUSA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

CNSX:AUSA Future Dividends Estimate Data
Date (Data in CA$) Dividend per Share (annual) Avg. No. Analysts
2021-03-31
2020-03-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Australis Capital has not reported any payouts.
  • Unable to verify if Australis Capital's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Australis Capital's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Australis Capital has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Australis Capital's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Australis Capital afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Australis Capital has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

AUSA Management

 What is the CEO of Australis Capital's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Scott Dowty
COMPENSATION CA$539,523
AGE 51
TENURE AS CEO 1.3 years
CEO Bio

Mr. Scott Dowty serve as Director and Chief Executive Officer at Australis Capital Inc. since June 15, 2018. Mr. Dowty has been Chief Revenue Officer at Apriva, LLC since September 20, 2017. Mr. Dowty served as an Executive Vice President of Enterprise Sales at CardConnect Corp. since September 17, 2016 until March 4, 2017. Mr. Dowty served as Chief Revenue Officer of CardConnect Corp. since October 2014. He started his payments career after nearly 10 years of founding, building and successfully selling startups in Canada. He served as Chief Revenue Officer and Executive Vice President through their acquisition by Fintech Development Corp. He has been a Director of Body and Mind, Inc. since November 5, 2018. Mr. Dowty held a number of executive management positions at First Data International. He joined First Data in 2000 as Vice President of National Sales and later served as Senior Vice President of Sales for Latin America and Canada and as General Manager and Country Manager for Canada. Before joining First Data, he worked for CIBC Card Products, (now Global Payments Canada), one of Canada's largest merchant processors. He began his professional career in 1990, when he founded and eventually sold a toiletry manufacturing, distribution and marketing company. Mr. Dowty’s extensive operational capital markets experience in the International fintech and gambling sectors is closely aligned to the regulatory path of the U.S. cannabis industry.

CEO Compensation
  • Insufficient data for Scott to compare compensation growth.
  • Scott's remuneration is higher than average for companies of similar size in Canada.
Management Team Tenure

Average tenure of the Australis Capital management team in years:

0.9
Average Tenure
  • The average tenure for the Australis Capital management team is less than 2 years, this suggests a new team.
Management Team

Scott Dowty

TITLE
CEO & Director
COMPENSATION
CA$540K
AGE
51
TENURE
1.3 yrs

Michael Carlotti

TITLE
Executive VP & CFO
COMPENSATION
CA$528K
TENURE
1 yrs

Cam Birge

TITLE
Strategic Advisor
COMPENSATION
CA$100K
AGE
66
TENURE
1 yrs

Lou Kiara Marcos

TITLE
Vice President of Operations & Culture

Alex Han

TITLE
Vice President of Accounting

Brent Reuter

TITLE
Senior Vice President of Investor Relations & Strategy
TENURE
0.3 yrs

Daniel Norr

TITLE
Senior VP & General Counsel
TENURE
0.8 yrs

Ashton Clapp

TITLE
Director Communications & Awareness

Casey Jones

TITLE
Director Business Development

Randon Marcos

TITLE
Director of Business Development
TENURE
0.7 yrs
Board of Directors Tenure

Average tenure of the Australis Capital board of directors in years:

1.3
Average Tenure
  • The average tenure for the Australis Capital board of directors is less than 3 years, this suggests a new board.
Board of Directors

Scott Dowty

TITLE
CEO & Director
COMPENSATION
CA$540K
AGE
51
TENURE
1.3 yrs

Roger Swainson

TITLE
Independent Director
TENURE
1.3 yrs

John Dover

TITLE
Independent Director
TENURE
1.3 yrs

Harry DeMott

TITLE
Director
AGE
52
TENURE
0.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
20. Mar 19 Buy Roger Swainson Individual 25. Oct 18 25. Oct 18 50,000 CA$2.03 CA$101,500
05. Mar 19 Buy Roger Swainson Individual 05. Mar 19 05. Mar 19 50,000 CA$0.98 CA$49,000
28. Nov 18 Buy Venture Communications, Ltd. Company 27. Nov 18 27. Nov 18 9,230 CA$2.03 CA$18,737
09. Nov 18 Buy District Ventures Company 02. Nov 18 02. Nov 18 189,448 CA$1.65 CA$312,589
09. Nov 18 Buy Venture Communications, Ltd. Company 25. Oct 18 02. Nov 18 191,111 CA$2.04 CA$388,001
X
Management checks
We assess Australis Capital's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Australis Capital has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

AUSA News

Simply Wall St News

AUSA Company Info

Description

Australis Capital Inc. is a venture capital specializing in early-stage but not limited to equity positions and/or debt in both public and private companies, financings in exchange for royalties or other distribution streams, and control share acquisitions and buyouts. It seeks to identify and invest in United States and abroad in cannabis and real estate assets. Australis Capital Inc. is based in Las Vegas, Nevada and additional offices in Vancouver, Canada.

Details
Name: Australis Capital Inc.
AUSA
Exchange: CNSX
Founded:
CA$118,323,472
159,896,584
Website: http://www.ausacap.com
Address: Australis Capital Inc.
376 East Warm Springs Road,
Suite 190,
Las Vegas,
Nevada, 89119,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX AUSA Common Shares Canadian National Stock Exchange CA CAD 19. Sep 2018
OTCPK AUSA.F Common Shares Pink Sheets LLC US USD 19. Sep 2018
DB AC4 Common Shares Deutsche Boerse AG DE EUR 19. Sep 2018
Number of employees
Current staff
Staff numbers
0
Australis Capital employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/22 00:47
End of day share price update: 2019/09/20 00:00
Last estimates confirmation: 2019/08/08
Last earnings filing: 2019/08/28
Last earnings reported: 2019/06/30
Last annual earnings reported: 2019/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.